FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4247641510> ?p ?o ?g. }

• W4247641510 endingPage "894" @default.
• W4247641510 startingPage "891" @default.
• W4247641510 abstract "No AccessJournal of Urology1 Feb 2002Intracavitary bacillus calmette-guerin in the treatment of superficial bladder tumors A. Morales, D. Eidinger, and A.W. Bruce A. MoralesA. Morales Department of Urology, Queen's University, Kingston, Ontario, Canada Department of Microbiology and Immunology, Queen's University, Kingston, Ontario, Canada Current address: Laboratory of Immunodiagnosis, Building 8, Room 118, National Institutes of Health, Bethesda, Maryland 20014. More articles by this author , D. EidingerD. Eidinger Department of Urology, Queen's University, Kingston, Ontario, Canada Department of Microbiology and Immunology, Queen's University, Kingston, Ontario, Canada More articles by this author , and A.W. BruceA.W. Bruce Department of Urology, Queen's University, Kingston, Ontario, Canada Department of Microbiology and Immunology, Queen's University, Kingston, Ontario, Canada More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(02)80294-4AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Patients with recurrent superficial bladder tumors have been treated by vesical and intradermal administration of Bacillus Calmette-Guerin. The pattern of recurrence in 9 patients has been altered favorably. Although the findings are still preliminary they appear to hold promise of a new therapeutic approach to the treatment of a group of neoplasms for which effective therapy is still lacking. References 1. : Thiotepa bladder instillations: therapy and prophylaxis for superficial bladder tumors. J. Urol.1969; 101: 711. Google Scholar 2. : The management of superficial bladder tumors with intravesical epodyl. Brit. J. Urol.1973; 45: 84. Google Scholar 3. : Treatment of multiple superficial papillary tumors of the bladder by intracavitary yttrium-90. J. Urol.1975; 113: 480. Link, Google Scholar 4. : Immune response to urinary bladder tumours in man. Int. J. Cancer1970; 5: 39. Google Scholar 5. : Correlation among host immunocompetence and tumor stage, tumor grade and vascular permeation in transitional carcinoma. J. Urol.1973; 110: 526. Link, Google Scholar 6. : Immunotherapy of guinea pig cancer with BCG. Cancer1974; 34: 1532. Google Scholar 7. : Surface markers on human T and B lymphocytes. I. A large population of lymphocyte forming nonimmune rosettes with sheep red blood cells. J. Exp. Med.1973; 136: 207. Google Scholar 8. : Increased cytolytic activity of a subcellular fraction from mouse liver after B.C.G. injection. Lancet1973; 2: 1476. Google Scholar 9. : BCG stimulation of immune responsiveness in patients with malignant melanoma. Cancer1973; 32: 321. Google Scholar 10. : Results of administering B.C.G. to patients with melanoma. Lancet1974; 2: 1096. Google Scholar 11. : Chemoimmunotherapy for cancer of the head and neck. Amer. J. Surg.1973; 126: 507. Google Scholar 12. : Bacillus Calmette-Guerin in the treatment of adenocarcinoma of the kidney. J. Urol.1976; 115: 37. Google Scholar 13. : The effects of BCG on the dog bladder. Invest. Urol.1975; 12: 423. Google Scholar 14. : Histopathology of Mycobacterium bovis (BCG)-mediated tumor regression. Nat. Cancer Inst. Monogr.1972; 35: 345. Google Scholar 15. : Cell-mediated immunity to human tumors. Abrogation by serum factors and nonspecific effects of oral BCG therapy. Arch. Surg.1973; 107: 261. Google Scholar 16. : Immune reactivity in renal cancer a sequential study. J. Urol.1976; 115: 510. Link, Google Scholar 17. : Peripheral lymphocyte counts in breast carcinoma. An index of immune competence. Cancer1974; 34: 2014. Google Scholar © 2002 by American Urological Association, IncFiguresReferencesRelatedDetailsCited byDeb A, Wilson S, Rove K, Kumar B, Koul S, Lim D, Meacham R and Koul H (2011) Potentiation of Mitomycin C Tumoricidal Activity for Transitional Cell Carcinoma by Histone Deacetylase Inhibitors In Vitro [RETRACTED]Journal of Urology, VOL. 186, NO. 6, (2426-2433), Online publication date: 1-Dec-2011.DOVEDI S, KIRBY J, ATKINS H, DAVIES B and KELLY J (2018) CYCLOOXYGENASE-2 INHIBITION: A POTENTIAL MECHANISM FOR INCREASING THE EFFICACY OF BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR BLADDER CANCERJournal of Urology, VOL. 174, NO. 1, (332-337), Online publication date: 1-Jul-2005. Volume 167Issue 2 Part 2February 2002Page: 891-894 Advertisement Copyright & Permissions© 2002 by American Urological Association, IncMetricsAuthor Information A. Morales Department of Urology, Queen's University, Kingston, Ontario, Canada Department of Microbiology and Immunology, Queen's University, Kingston, Ontario, Canada Current address: Laboratory of Immunodiagnosis, Building 8, Room 118, National Institutes of Health, Bethesda, Maryland 20014. More articles by this author D. Eidinger Department of Urology, Queen's University, Kingston, Ontario, Canada Department of Microbiology and Immunology, Queen's University, Kingston, Ontario, Canada More articles by this author A.W. Bruce Department of Urology, Queen's University, Kingston, Ontario, Canada Department of Microbiology and Immunology, Queen's University, Kingston, Ontario, Canada More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W4247641510 created "2022-05-12" @default.
• W4247641510 creator A5014614954 @default.
• W4247641510 creator A5025873791 @default.
• W4247641510 creator A5040070300 @default.
• W4247641510 date "2002-02-01" @default.
• W4247641510 modified "2023-10-06" @default.
• W4247641510 title "Intracavitary bacillus calmette-guerin in the treatment of superficial bladder tumors" @default.
• W4247641510 cites W133776204 @default.
• W4247641510 cites W1977602326 @default.
• W4247641510 cites W1997746637 @default.
• W4247641510 cites W2032985765 @default.
• W4247641510 cites W2054281103 @default.
• W4247641510 cites W2068804709 @default.
• W4247641510 cites W2071819282 @default.
• W4247641510 cites W2085997553 @default.
• W4247641510 cites W2116298488 @default.
• W4247641510 cites W2162763387 @default.
• W4247641510 cites W2395520298 @default.
• W4247641510 cites W2413887039 @default.
• W4247641510 cites W2419414287 @default.
• W4247641510 cites W2472408552 @default.
• W4247641510 cites W4298353568 @default.
• W4247641510 doi "https://doi.org/10.1016/s0022-5347(02)80294-4" @default.
• W4247641510 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11905917" @default.
• W4247641510 hasPublicationYear "2002" @default.
• W4247641510 type Work @default.
• W4247641510 citedByCount "52" @default.
• W4247641510 countsByYear W42476415102012 @default.
• W4247641510 countsByYear W42476415102014 @default.
• W4247641510 countsByYear W42476415102015 @default.
• W4247641510 countsByYear W42476415102016 @default.
• W4247641510 countsByYear W42476415102017 @default.
• W4247641510 countsByYear W42476415102019 @default.
• W4247641510 countsByYear W42476415102020 @default.
• W4247641510 countsByYear W42476415102021 @default.
• W4247641510 countsByYear W42476415102022 @default.
• W4247641510 countsByYear W42476415102023 @default.
• W4247641510 crossrefType "journal-article" @default.
• W4247641510 hasAuthorship W4247641510A5014614954 @default.
• W4247641510 hasAuthorship W4247641510A5025873791 @default.
• W4247641510 hasAuthorship W4247641510A5040070300 @default.
• W4247641510 hasConcept C121608353 @default.
• W4247641510 hasConcept C126322002 @default.
• W4247641510 hasConcept C126894567 @default.
• W4247641510 hasConcept C141071460 @default.
• W4247641510 hasConcept C2776694085 @default.
• W4247641510 hasConcept C2776755627 @default.
• W4247641510 hasConcept C2779968505 @default.
• W4247641510 hasConcept C2780352672 @default.
• W4247641510 hasConcept C2780653484 @default.
• W4247641510 hasConcept C2781321516 @default.
• W4247641510 hasConcept C29456083 @default.
• W4247641510 hasConcept C2992225637 @default.
• W4247641510 hasConcept C59822182 @default.
• W4247641510 hasConcept C71924100 @default.
• W4247641510 hasConcept C86803240 @default.
• W4247641510 hasConceptScore W4247641510C121608353 @default.
• W4247641510 hasConceptScore W4247641510C126322002 @default.
• W4247641510 hasConceptScore W4247641510C126894567 @default.
• W4247641510 hasConceptScore W4247641510C141071460 @default.
• W4247641510 hasConceptScore W4247641510C2776694085 @default.
• W4247641510 hasConceptScore W4247641510C2776755627 @default.
• W4247641510 hasConceptScore W4247641510C2779968505 @default.
• W4247641510 hasConceptScore W4247641510C2780352672 @default.
• W4247641510 hasConceptScore W4247641510C2780653484 @default.
• W4247641510 hasConceptScore W4247641510C2781321516 @default.
• W4247641510 hasConceptScore W4247641510C29456083 @default.
• W4247641510 hasConceptScore W4247641510C2992225637 @default.
• W4247641510 hasConceptScore W4247641510C59822182 @default.
• W4247641510 hasConceptScore W4247641510C71924100 @default.
• W4247641510 hasConceptScore W4247641510C86803240 @default.
• W4247641510 hasIssue "2 Part 2" @default.
• W4247641510 hasLocation W42476415101 @default.
• W4247641510 hasLocation W42476415102 @default.
• W4247641510 hasOpenAccess W4247641510 @default.
• W4247641510 hasPrimaryLocation W42476415101 @default.
• W4247641510 hasRelatedWork W2352656325 @default.
• W4247641510 hasRelatedWork W2370208313 @default.
• W4247641510 hasRelatedWork W2384311157 @default.
• W4247641510 hasRelatedWork W2395732460 @default.
• W4247641510 hasRelatedWork W2480000808 @default.
• W4247641510 hasRelatedWork W2771908915 @default.
• W4247641510 hasRelatedWork W324577642 @default.
• W4247641510 hasRelatedWork W4205910527 @default.
• W4247641510 hasRelatedWork W2118673085 @default.
• W4247641510 hasRelatedWork W2610028178 @default.
• W4247641510 hasVolume "167" @default.
• W4247641510 isParatext "false" @default.
• W4247641510 isRetracted "false" @default.
• W4247641510 workType "article" @default.